Beam Therapeutics
AUDIT: Beam Therapeutics: The Clinical Dead Zone
A forensic audit of Beam Therapeutics (BEAM-302) reveals severe liver toxicity, a 12-month FDA hold, and executive de-risking in the gene surgery space.
Beam Therapeutics
A forensic audit of Beam Therapeutics (BEAM-302) reveals severe liver toxicity, a 12-month FDA hold, and executive de-risking in the gene surgery space.
Intellia Therapeutics
Audit of Intellia Therapeutics' in-vivo CRISPR trials. Examining the MAGNITUDE Phase 3 data, the 'Sepsis Pivot', and the severe clinical solvency risks.